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and remission to compare biologic strategies in France, aligned
with RA treatment goals. The results suggest that when used as
the second biologic agent after an inadequate response to one
anti-TNF agent, abatacept appears signiﬁcantly more efﬁcacious
and cost-effective than rituximab.
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OBJECTIVES: To evaluate cost-effectiveness of TNF-a inhibitors
(adalimumab, etanercept and inﬂiximab) in the treatment of
ankylosing spondylitis (AS) in polish settings. METHODS:
Markov model was adapted for two health states: response and
non-response according to ASAS20 criteria and cycle time was 3
months. Analysis was performed from the perspective of public
payer (National Heath Fund) in the 1 year and life-time horizons.
Costs analyzed: acquisition costs of drugs, drug administration
and treatment monitoring costs, adverse events treatment costs,
AS hospitalization costs, tuberculosis monitoring and treatment
costs. Health outcomes included quality-adjusted life-year
(QALY). Data from systematic review of published randomized
clinical trials were used to evaluate transition probabilities
during anti-TNF-a or comparator (standard AS therapy—
NSAID and/or DMARD’s) treatment. Utility values were calcu-
lated from BASFI, BASDAI, sex and age data based on published
algorithm. Costs and effects were discounted 5% annually.
Univariate and probabilistic sensitivity analyses were performed.
Values are presented in PLN (exchange rate: 1 Euro = 3.40 PLN).
RESULTS: In the base-case analysis QALY gains of 0.063 and
0.302 were estimated for patients treated with adalimumab,
etanercept or inﬂiximab in 1-year and life-time horizon, respec-
tively. ICER/QALY in one year horizon was 597,455, 597,169
and 796,076 PLN/QALY for adalimumab, etanercept and inﬂix-
imab, respectively. In life-time horizon ICER/QALY was
405,430, 405,235 and 471,707 PLN/QALY for adalimumab,
etanercept and inﬂiximab, respectively. CONCLUSIONS: Anti-
TNF-alfa treatment is currently unattractive for all AS patients in
polish health care settings, thus further analysis are needed to
identify subgroups of patients who beneﬁt most to ensure effec-
tive resources allocation.
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OBJECTIVES: To evaluate the cost-effectiveness of etanercept
combination therapy with methotrexate (MTX) versus rituximab
with MTX for rheumatoid arthritis (RA) from a payer’s perspec-
tive in Colombia. METHODS: A literature-based decision ana-
lytic model was constructed with a one year time horizon to
compare the cost-effectiveness of etanercept 25 mg twice-
weekly + MTX versus rituximab 2 ¥ 1000mg infusion + MTX in
RA patients with an inadequate response to disease-modifying
anti-rheumatic drugs. The primary measure of clinical effective-
ness was based on remission (Disease Activity Score 28 joint
count < 2.6). The model incorporated major and minor infec-
tious events, discontinuation due to lack of efﬁcacy or adverse
event, and rituximab re-treatment within the one year time-
horizon. Drug costs were based on average wholesale price. Cost
of managing adverse events and infusion costs were compiled
based on queries to Colombian rheumatologists. Sensitivity
analysis was conducted in the 30% price range and efﬁcacy
parameters for etanercept and rituximab. RESULTS: One year
total treatment costs for rituximab were COL$37,442,828 and
COL$39,825,456 for etanercept. The percent of patients achiev-
ing remission was 3% for rituximab and 27% for etanercept at
the end of 1 year. The incremental cost-effectiveness ratio (ICER)
was COL$9931,754 per additional patient achieving remission.
The number needed to treat was 29 for rituximab and 5 for
etanercept. Given a hypothetical budget of COL$1,000,000,000,
the number of patients achieving remission was 7 for etanercept
and 1 for rituximab. Sensitivity analysis showed that etanercept
continued to have more patients achieving remission than ritux-
imab even if the drug cost and efﬁcacy was varied by 30%
given a deﬁned budget. CONCLUSIONS: The results suggest
that etanercept appears to be cost-effective compared to ritux-
imab. Additionally, more patients can be successfully treated to
remission with etanercept than rituximab given a deﬁned budget.
These ﬁndings were robust for plausible ranges of effectiveness
and drug acquisition costs.
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OBJECTIVES: The clinical beneﬁt of initial combination therapy
with inﬂiximab in patients with rheumatoird arthritis was estab-
lished in BeSt, a randomized clinical trial assessing the impact of
four treatment strategies in patients recently (less than 2 years)
diagnosed with RA. Treatment options were sequential mono-
therapy with DMARDs (group 1), step-up combination therapy
(group 2), initial combination therapy with tapered high-dose
prednisone (group 3), and initial combination therapy with
inﬂiximab (group 4). The cost-effectiveness of initial combina-
tion therapy with inﬂiximab vs. sequential DMARD mono-
therapy was evaluated. METHODS: Data on clinical outcomes
(Health Assessment Questionnaire [HAQ]) were extracted from
the two-year publication of BeSt and extrapolated to ﬁve years.
Medical resource use and drug costs (2006 £) were obtained
from the British National Formulary and two systematic NICE
reviews of TNF-a inhibitors in RA. Model outcomes, from a UK
payer perspective, included cost per one-point improvement in
HAQ and cost per quality-adjusted life-year (QALY); cost and
beneﬁt were discounted at 3.5%. HAQ scores were translated
into QALYs using an established algorithm. Probabilistic sensi-
tivity analyses were conducted to determine the impact of drug
cost, HAQ improvement, and translation between HAQ and
QALY. RESULTS: Initial combination therapy with prednisone
or inﬂiximab led to earlier HAQ improvement vs. sequential
monotherapy and step-up combination therapy. Cumulative
costs in group 1 increased from £1,155 to £15,875; costs in
group 4 rose from £8,131 to £22,155. QALYs improved more in
group 4 (0.70 to 3.30) than in group 1 (0.62 to 2.91). Cost per
QALY declined from £92,764 (year 1) to £15,965 (year 5) for
initial combination therapy with inﬂiximab vs. sequential mono-
therapy. Results were not sensitive to changes in drug cost, HAQ,
or the conversion algorithm. CONCLUSIONS: Higher costs
associated with the earlier use of inﬂiximab are offset by this
regimen’s clinical beneﬁt over time.
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